There is a need for new therapeutic targets with which to prevent Alzheimer's disease (AD), a major contributor to agingrelated cognitive decline. Here we report the construction and validation of a molecular network of the aging human frontal cortex. Using RNA sequence data from 478 individuals, we first build a molecular network using modules of coexpressed genes and then relate these modules to AD and its neuropathologic and cognitive endophenotypes. We confirm these associations in two independent AD datasets. We also illustrate the use of the network in prioritizing amyloid-and cognition-associated genes for in vitro validation in human neurons and astrocytes. These analyses based on unique cohorts enable us to resolve the role of distinct cortical modules that have a direct effect on the accumulation of AD pathology from those that have a direct effect on cognitive decline, exemplifying a network approach to complex diseases.
T he incidence of late-onset AD is expected to triple in the United States by 2050 1 , yet no therapies are available to treat or prevent the disease 2 . Possible reasons for the continued failure of AD trials include the biological complexity of the disease and its phenotypic heterogeneity 3 . Recent genome-wide association studies (GWAS) have identified new potential therapeutic targets involved in endocytosis, metabolism and inflammation 4 . However, it has been difficult to transition from mostly noncoding susceptibility variants to molecular mechanisms that lead to the characteristic accumulation of β -amyloid and helical filament tau (PHFtau) pathology, as well as the subsequent cognitive decline of AD.
Here we describe an analysis of participants from two large, longitudinal cohort studies of aging (total n = 478), as well as a validation set (n = 82), which have careful assessments of both antemortem cognitive function and postmortem neuropathologic burden. We hypothesized that RNA sequencing (RNA-seq) data from the dorsal lateral prefrontal cortex (DLPFC) would enable us to identify coherent intermediate cellular mechanisms that are associated with cognitive decline and/or neuropathological changes. Noting that dynamic genomic measurements such as RNA-seq reflect the collective effect of upstream, downstream and diseasecorrelated processes, we use a series of network-based approaches that account for known and hidden confounding factors to enrich our results for likely upstream associations.
A network-based perspective provides a more nuanced molecular definition of complex disease than do traditional single-gene associations because it provides a natural framework with which to assemble disparate single gene findings into disease mechanisms [5] [6] [7] [8] . Transcriptomic data can be used to identify groups of coexpressed genes, or modules, that represent cellular processes and can be related to phenotypes of interest 7, [9] [10] [11] . This approach offers an unsupervised and tissue-specific perspective that identifies transcriptional programs related to disease phenotypes, independent of historical bias arising from research on particular genes and pathways 10 .
Coexpression approaches have identified genes associated with a syndromic diagnosis of AD dementia 12, 13 . However, these approaches have never been applied to large cohorts with quantitative measurements of both AD neuropathology and cognitive decline. Because neuropathologic burden and cognition show important divergence in AD 14, 15 , jointly modeling both aspects of the disease may better capture the relationship between molecular events and different stages of the disease process. Furthermore, previous efforts did not distinguish between transcriptomic patterns that are indirectly associated with AD phenotypes via a chain of intermediaries from those that are directly associated 12 . Here, we build on previous work to address these limitations. Our approach, called gene moduletrait network analysis (MTN) ( Fig. 1) , constructs gene expression modules and identifies those that are directly associated with cognitive decline, conditioned on neuropathology and other large-scale transcriptomic changes in the aging brain. We confirm the biological plausibility of this systems biology analysis in five other types of independent datasets. Finally, we test the identified associations in a relevant human model system to functionally characterize the Results Data origin and phenotypes. Data were derived from subjects enrolled in the Religious Orders Study (ROS) or the Rush Memory and Aging Project (MAP), two prospective clinical-pathologic cohort studies of aging and dementia. All participants lack dementia at enrolment, have annual clinical evaluations and have agreed to brain donation. At death, each brain undergoes a structured, quantitative neuropathologic assessment (see Methods). The two studies (collectively referred to as ROSMAP) share clinical and neuropathological standards, allowing joint analyses of the data. Individual trajectories of cognitive decline are calculated from longitudinal cognitive measures that include up to 20 yearly evaluations 16, 17 . For this study, we used data from 478 participants, with a mean age at death of 88.7 years. Over the course of the study, some subjects experienced cognitive decline, and at the time of death 32% remained cognitively unimpaired, 27% had mild cognitive impairment, 39% had a diagnosis of AD dementia, and 2% had another form of dementia. Furthermore, 58% of these subjects received a diagnosis of pathologic AD. However, 46% of these individuals with pathologic AD did not have clinical dementia, illustrating the welldescribed divergence of pathologic and clinical diagnoses of AD dementia ( Supplementary Table 1 ).
Our analysis included five phenotypic traits related to AD. Two of these traits are clinical measures: a clinical diagnosis of AD dementia proximate to death (clinical AD) and a continuous measure of cognitive decline over time quantified as a per-subject slope of the cognitive decline trajectory from a linear mixed-effects model 18 . The three pathology variables include continuous measures of PHFtau tangle density and β -amyloid burden (both averaged over multiple regions) and a binary diagnosis of pathologic AD (see Methods).
In these subjects, we saw the expected strong association of the APOE ε 4 haplotype with clinical AD (P = 5.55 × 10 −16 , using logistic regression to model the number of ε 4 alleles while accounting for age and sex), but even this unique genetic risk factor explains little of the variance in clinical AD (2.2% variance explained) or cognitive decline (5.1% variance explained). Subsequent inclusion of the other 21 AD susceptibility variants to represent the known genetic architecture of AD only explains 2.1% of clinical AD and 7.6% of cognitive decline. Thus, while these robustly validated susceptibility variants provide important insights into risk factors that contribute to AD, they capture only a small fraction of the biology of the disease, much of which may be influenced by nongenetic risk factors. The transcriptome, with its dynamic nature that is molded by environmental exposures and life experiences, provides a complementary approach to therapeutic target discovery in AD.
RNA-seq gene expression data and standard association analysis.
After rigorous quality control evaluations, we retained RNA-seq data from the DLPFC of 478 individuals for downstream analyses; an average of 95 million (median 90 million) paired-end reads was available for each subject. RNA-seq data were then normalized to account for the effects of many known biological and technical confounding factors (Methods and Supplementary Fig. 1 ). Genes with low expression were removed to reduce the influence of technical noise, resulting in quantified expression for 13,484 unique genes (25,400 transcripts) (Methods).
We first performed a standard transcriptome-wide association study to identify genes whose expression levels associate with AD-related phenotypes. The expression levels of thousands of genes associated with these traits at a false discovery rate (FDR) < 0.05 (Supplementary Table 2 and Fig. 2a ). The combination of cognitive and pathological phenotypes allows us to compare their respective effects on gene expression, and we observed that cognitive decline was associated with the largest number of genes (3,025 genes at FDR < 0.05), compared to the other AD traits. Accordingly, the key clinical variable of cognitive decline may implicate additional molecular mechanisms in AD, beyond those found by neuropathological markers of AD. Indeed, a majority of age-related cognitive decline cannot be accounted for by current measures of AD or other age-related pathologies 14 . Overall, using the π 1 statistic 19 , we estimated that 55-90% of the associated genes are shared among these correlated AD-related traits ( Supplementary Fig. 2 ). The large number of associated genes highlights the need to assemble these findings into coherent biological processes that are directly associated with specific disease-relevant endpoints.
Constructing the nodes of our module-trait network. To identify coherent cellular processes that impact AD phenotypes, we used the MTN approach. The goal of this approach is to go beyond single gene-level associations in defining robust molecular mechanisms while avoiding the limitations of pathways derived from ontology databases. MTN summarizes large-scale transcriptome changes into gene modules and prioritizes specific genes within a module for further experiments. MTN consists of three steps. As described method to prioritize modules and genes directly related to AD-related traits in our study. a, Inputs to the MTN method are (i) AD pathological traits of amyloid and tau measurements, which are aggregated over multiple brain regions; (ii) slope of cognitive decline before death aggregated over multiple neuropsychologic tests; and (iii) average expression of coexpressed gene sets (modules), detected in the same subjects using consensus clustering. b, These three inputs are combined using conditional independence relationships (via Bayesian networks) to identify direct relationships among coexpression modules, AD traits and cognitive decline (cog). c, The disease relevance of top predicted genes is tested experimentally in an astrocyte and iPSC-induced neuron in vitro system.
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in detail below, we first identify groups of coexpressed genes, or 'modules' , which we validate in other datasets. Coexpressed gene sets represent the outcome of transcriptional regulatory mechanisms that include transcription factors, chromatin conformation and latent factors that generate correlations, such as the proportion of different cell types present in the sampled tissue 10 . In the second step, we determine which modules have direct relationships with cognitive decline and other AD traits using Bayesian networks to prune correlations between modules and AD-related traits that are indirect. In the final analytical step, we select a top-scoring module and prioritize genes that are uniquely influential within that module for validation in our in vitro model systems.
In the first step of MTN, we applied the SpeakEasy consensus clustering algorithm 20 to our RNA-seq data and identified 47 mutually exclusive modules ranging in size between 20 and 556 gene members (Supplementary Table 3 , Supplementary Fig. 3 and Methods). We note that the clustering assignment identified by the SpeakEasy algorithm overlapped substantially with those proposed by the frequently used WGCNA algorithm 21 (Methods  and Supplementary Table 4 ); however, we chose to use SpeakEasy because of its state-of-the-art performance on benchmark and realworld datasets 20 .
We validated the biological coherence of the 47 modules from five perspectives: (i) Gene Ontology (GO) functional enrichment analysis, (ii) module coherence ('preservation') in a separately processed set of ROSMAP samples and an entirely independent cohort, (iii) concordance with co-regulation observed in epigenomic data generated from the same ROSMAP brains, (iv) concordance with brain gene expression data from multiple AD mouse models, and (v) cell-type-specific expression. In the first validation, we found that 29 (62%) of the modules were enriched for at least one GO functional category (Bonferroni P < 0.01, Supplementary . The x axis shows the signed association strength (signed -log 10 P) between each module and cognitive decline. Larger points (modules) are those that we deem to most strongly represent each of the four main brain cell types: neurons (m187), microglia (m116), oligodendrocytes (123) and astrocytes (m107) (see Methods). c, Association strength (quantified as -log 10 P) between each of the 47 modules of coexpressed genes (visualized as vertical bars) and each of the five tested AD-related trait (x axis). The dashed line depicts the Bonferroni-adjusted significance threshold at the module level (P < 0.001). For ease in visualization, only some of the modules that pass Bonferroni threshold are labeled. d, Strength and direction of each module's association (signed -log 10 P) for association with a binary diagnosis of pathological AD in our ROSMAP study on the y axis. The x axis shows the signed association strengths between each module and pathological AD in a microarray dataset from Zhang et al. 12 . Specifically, the modules are defined using the ROSMAP samples, and their definitions are projected onto the Zhang dataset. The area of each point represents the size of the module (i.e., number of assigned genes). The color of the point reflects the significance of the association in a meta-analysis of the ROSMAP and Zhang modules. The light orange boxes highlight those modules that are significantly associated with pathologic AD diagnosis in the microarray (Zhang) dataset. The green box highlights the modules that are significantly associated with a pathologic AD diagnosis in the ROSMAP data.
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which is in the range of enrichments seen in other studies 10 . Second, we assessed whether the 47 modules are preserved in (i) a previously published DLPFC microarray dataset of 229 persons with both pathologic and clinical AD 12 and (ii) RNA-seq data from an independent set of 82 ROSMAP subjects. Using the z-summary statistic, which summarizes multiple measures of module preservation 22 , we observed significant evidence for preservation in 45 of the 47 modules in the independent microarray dataset and all 47 modules in the separately-processed ROSMAP subjects (Bonferroni P < 0.05) ( Supplementary Fig. 4a ). Third, we assessed the robustness of these modules from a transcriptional regulatory perspective with data on histone H3 Lys9 acetylation (H3K9ac) chromatin immunoprecipitation and sequencing (ChIP-seq) generated from the same DLPFC samples. The H3K9ac histone mark is found near active transcription start sites and enhancers 23 , and so coacetylation would be expected for genes that are coexpressed at the RNA level. In our data, we detected coacetylation for 32 of the 47 RNA-seq-defined modules, indicating that the modules reflect, in part, the underlying epigenomic architecture ( Supplementary  Fig. 4a ). Fourth, we also found that 31% of the modules are significantly preserved (Bonferroni P < 0.05) in gene expression data derived from the cortex of several pathology-based mouse models of AD 24 ( Supplementary Fig. 4a ), which may help to prioritize those results that can be pursued further in mouse models. Fifth, we find that 13 modules are strongly enriched for cell-type-specific genes, including those from microglia, astrocytes, oligodendrocytes and two neuronal subtypes (GABAergic and pyramidal neurons) ( Fig. 2b and Supplementary Table 6 ) based on purified neuronal and non-neuronal cell populations derived from the mouse brain 25 (Methods). Thus, some of the modules capture previously identified cell-specific gene sets. Each of these five validations in parallel and orthogonal datasets indicates that gene membership of these modules is reproducible and biologically meaningful.
We next assessed the association between each module and each phenotypic trait, (Methods). Overall, 11 modules were associated (Bonferroni adjusted at module level, P < 10 −3 ) with cognitive decline, AD dementia or AD pathology traits ( Fig. 2c and Supplementary Table 7 ). Consistent with the gene-level results, cognitive decline was associated with the greatest number of modules. In general, modules enriched for GO categories related to immunity, mitochondria, cell cycle and transcriptional regulation showed a positive correlation with β -amyloid, AD and cognitive decline, while modules for neuronal or synaptic function showed a negative correlation. To replicate the phenotypic associations of these modules, we projected them onto the largest previous AD brain microarray study 12 (the 'Zhang study') (Methods). Only a pathologically confirmed diagnosis of AD dementia is available in the Zhang study as an outcome, and we observed a strong concordance in both the strength and direction of the module-pathologic AD associations that we defined in ROSMAP subjects ( Fig. 2d) . Notably, we observed that the module-level trait associations were more similar between these two datasets than were the univariate gene-level trait associations, further reinforcing the utility of the module-level approach ( Supplementary Fig. 4b ).
Because variation in cell type proportions across individuals can drive coexpression patterns between genes, some moduletrait associations may be due to changes in cell type proportions that occur over the course of the disease ( Supplementary Fig. 5a,b ). Importantly, as we describe next, the identification of 'cell typespecific modules' enabled us to guide functional validation efforts and to comprehensively model and account for changes in cell type composition that may drive large-scale transcriptomic changes in AD at the bulk tissue level.
Identifying modules associated with disease in networks of the aging human brain. To separate a small number of direct mod-ule-trait associations from the larger number of indirect moduletrait correlations, we used Bayesian network inference 26 . A Bayesian network models the joint probabilities of a set of random variables as a directed acyclic graph. Here, the random variables represent module expression levels and trait values across individuals. Edges in a Bayesian network represent direct conditional dependencies between two variables: an arrow from X to Y in a Bayesian network indicates that a value taken by variable Y depends on the value taken by variable X, conditioned on all the other variables in the network (see Methods).
To limit the network size for more accurate inference, only modules associated with any of the three main AD-related traits (β -amyloid load, tau tangle density and cognitive decline) were included. We also included four modules representing the proportions of four main brain cell types-microglia, astrocytes, oligodendrocytes and neurons-to account for the effects of changes in cell population frequencies (Methods). In summary, the resulting Bayesian network consisted of 18 nodes: 11 nodes representing trait-associated modules, 3 trait nodes, and 4 'cell type modules' (Fig. 3a ).
Module 109 (m109) was the module most strongly associated with cognitive decline, conditioned on all other correlated modules and modules that represent cell type proportions ( Fig. 3a ). It consists of 390 genes with diverse functions. Prominent functions that are enriched in this module relate to the regulation of the cell cycle and chromatin modification (Supplementary Table 5 ). The association of m109 with cognitive decline replicated in the independently processed set of 82 ROSMAP subjects (P = 0.006).
Relation of RNA-derived modules to the genetic architecture of AD. The APOE ε 4 haplotype has a unique role in the disease given its large effect size (odds ratio > 3 for one copy of the APOE ε 4 haplotype) and substantial frequency in human populations 27 . Therefore, we evaluated its effect on m109 and found that APOE ε 4 had a modest association with higher m109 expression (nominal P = 0.03, Wilcoxon test, Supplementary Fig. 6 ), consistent with this haplotype's known associations with accumulation of β -amyloid pathology and cognitive decline 28 . In a conditional association analysis (Methods), after accounting for the APOE ε 4 haplotype, m109 remained strongly associated with both pathological AD (effect magnitude reduced by 13%, adjusted P = 0.0027) and cognitive decline (effect magnitude reduced by 7.4%, adjusted P = 5.03 × 10 −10 ), implying that the effect of m109 is largely independent of this susceptibility haplotype. We extended our genetic analysis of m109 to other common AD susceptibility variants 4 that, in earlier studies, displayed very little or no association with neuropathologic features of AD 29,30 . The 21 common AD variants did not associate with m109 in trans-eQTL (expressed quantitative trait locus) analysis, consistent with the observed sparsity of trans associations (trans-eQTLs) reported in studies with larger sample sizes 31 .
We also assessed whether any of the modules are enriched for genes found in the vicinity of AD variants (nearest genes, as previously reported 4 ) and found one enriched module, m116 (P = 0.0018 using the INRICH algorithm 32 ), which mostly contains microglial genes ( Supplementary Table 6 ). However, m116 was not directly associated with cognitive decline, AD pathology or AD dementia in this dataset (Supplementary Table 7 ). But it was associated with age (P = 0.003), highlighting the important role of advancing age in AD susceptibility and the fact that AD GWAS studies use a clinical diagnosis of AD and often younger control subjects to achieve very large sample sizes.
Finally, for completeness, we tested the association between the 21 common AD susceptibility alleles 4 and the 47 modules (i.e., a module-QTL analysis) and found no significant associations after multiple testing correction, consistent with the observation noted earlier that, while these susceptibility alleles are robust risk factors, they capture only a small fraction of the variance in these AD-related traits.
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Prioritizing genes in module 109 and testing their effect on extracellular β-amyloid levels. Because of m109's strong direct association with cognitive decline (P < 10 −9 ) (Figs. 3b and 3c), we elected to focus our functional evaluations on this module. In addition to cognitive decline, m109 was associated with β -amyloid pathology (P < 0.0001) ( Fig. 3a,d and Supplementary Table 7 ), but we note that a conditional correlation analysis indicated that the effect of m109 on cognitive decline is not fully mediated by the accumulation of β -amyloid. That is, m109 influences cognitive decline through both β -amyloid and non-β -amyloid processes. Owing to the absence of a cellular model of cognitive decline, we focused our validation effort on m109's association with β -amyloid load.
To prioritize genes in m109 for functional validation, we used several criteria: gene network connectivity (Fig. 4a,b and Supplementary Table 8 ), sufficient expression levels in cultured human astrocytes and/or induced human neurons (our two experimental systems), the magnitude of the gene-level association with our three AD-related phenotypes, and existing knowledge about gene function. We identified 21 genes within m109 that satisfied these criteria and were selected for experimental perturbation (see Methods).
For the 21 selected genes, an average of five short hairpin RNA constructs targeting each selected gene were tested for their knockdown of gene expression (Supplementary Table 9 ). To be included in our functional screen, genes had to have at least two shRNA constructs meeting our knockdown efficacy criteria of > 50% reduction in expression in the target cell type. Twelve genes (with 37 shRNA constructs) met this criterion in neurons and 14 genes (with 41 shRNA constructs) met this criterion in astrocytes; 11 genes were tested in both cell types ( Supplementary Table 10 ).
We performed 78 shRNA experiments to knock down the selected 14 genes in astrocytes and 12 genes in neurons. With these knockdown experiments, we measured extracellular levels of the pathogenic β -amyloid Aβ 42 peptide, which can be readily assayed in vitro and is related to the defining pathologic lesion in AD. We measured it in conditioned medium from primary astrocyte cultures as well as induced pluripotent stem cell (iPSC)-derived neuronal cultures following gene perturbation 
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NATURe NeURoscieNce (see Methods). These experiments included three types of negative controls, including empty vectors and vectors that only contained GFP (see Methods). Since m109 is positively correlated with β -amyloid burden ( Supplementary Table 7 ), the MTN approach predicts that a knockdown of expression would result in reduced β -amyloid levels. Using an ANOVA model that accounted for testing multiple constructs per gene (Methods), we evaluated the effect of each shRNA construct on extracellular Aβ 42 levels in contrast to the negative controls. In neurons, this outcome measure was not altered. By contrast, we identified two shRNA constructs targeting different genes, INPPL1 and PLXNB1, that exceeded the Bonferroni threshold of significance (P < 0.0012) in astrocytes ( Fig. 5a and Supplementary  Table 11 ) in our discovery screen. Two more constructs for these genes were found to meet a suggestive threshold (P < 0.024, determined as the reciprocal of the number of tests). Notably, these two genes are predicted to be upstream of the other tested genes in our Bayesian network model ( Fig. 4a ), are directly connected to one another and are two of the main hubs in the m109 coexpression network (Fig. 4b ).
To replicate these findings, we repeated the perturbation experiments, this time including four shRNA constructs for INPPL1 and three shRNA constructs for PLXNB1, as well as several negative and positive controls (see Methods). Specifically, as positive control we included shRNA constructs targeting APP, the parent protein of the Aβ 42 peptide. In these experiments, knockdown of both genes led to reduced extracellular levels of Aβ 42 in astrocyte cultures (P INPPL1 = 2 × 10 −4 and P PLXNB1 = 9 × 10 −6 ) ( Fig. 5b ). Overall, these results are consistent with the direction of m109 association, whereby higher m109 expression is seen with a greater β -amyloid load. We also immunostained frontal cortex from subjects with pathologic AD and showed that both INPPL1 and PLXNB1 were expressed at the protein level in astrocytes ( Fig. 5c ), confirming that these two genes were expressed in vivo in the human cell type used in the validation experiments. Astrocytes expressing these two genes are found in the vicinity of β -amyloid deposits (data not shown). These genes also are expressed in other cell types, such as neurons, and we cannot rule out the possibility that they may be implicated in AD in more than one cell type.
Having functionally confirmed a role in modulating extracellular levels of pathogenic Aβ 42 for these two m109 genes in vitro, we returned to our transcriptomic data to evaluate the magnitude of the effect of INPPL1 and PLXNB1 on β -amyloid load. Separately, they each account for a small proportion of the variance in β -amyloid load-2.8% for INPPL1 and 3.1% for PLXNB1-and, as is anticipated from the network model, are largely redundant, as together they explain 3.1% (adjusted R 2 ) of the variance in β -amyloid load (Fig. 5d ). This compares to < 1% variance of this trait explained by validated AD single nucleotide polymorphisms other than those in APOE. For example, the CR1 susceptibility allele explains 0.39% of variance in β -amyloid load in our data 33 . The effect of INPPL1 and PLXNB1 was somewhat stronger on cognitive decline: 5.5% of variance is explained by INPPL1, 4.4% by PLXNB1 and 5.4% (adjusted R 2 ) by both. More broadly, we assessed the degree to which these two genes capture the effect of the entire module. The m109 meta-feature explains 4.3% of the variance in β -amyloid burden and 8.5% of the variance in cognitive decline, and, after accounting for INPPL1 and PLXNB1, we see that some of the effect of m109 remains for β -amyloid (0.95% of the variance, P = 0.029) and more of the effect Fig. 4 | identifying specific genes within m109 for experimental follow-up. a, The estimated gene regulatory network (Bayesian network) for 112 selected genes in m109. Each gene is a node (circle) in the displayed graph. Colored nodes are those tested in our experimental systems (yellow: tested in both astrocytes and iPSC-derived neurons, blue: tested only in astrocytes, orange: tested only in iPSC-derived neurons). The area of each node is proportional to its node degree (total number of ingoing and outgoing edges per node). b, Coexpression values for the 112 genes shown in Fig. 3a , highlighting the substructure within the coexpression pattern of m109. Genes that are tested in our experimental systems are marked; they are found in each subset of the correlation matrix.
NATURe NeURoscieNce on cognitive decline persists (3.5% of the variance, P = 2.7 × 10 −5 ). Thus, while INPPL1 and PLXNB1 are important in m109, they do not appear to account for the effects of the entire module, suggest-ing that further validation work will be needed to identify additional driver genes for m109 and that they are likely to be driven by non-β -amyloid processes. 
NATURe NeURoscieNce
Discussion
We deployed MTN, a network-based approach, to identify coherent biological processes and specific genes associated with multiple AD-relevant traits. A key feature of our approach is the identification of unique, direct molecular-pathological-clinical relationships, which should reduce efforts spent on spurious disease associations and on indirect associations. Furthermore, we applied MTN to a cohort with measures of change in cognition over time, which is the most relevant clinical outcome measure of AD clinical trials for prodromal AD as well as mild cognitive impairment due to AD and AD dementia. This framework and our data allowed us to identify cellular processes in the human cortex that directly relate to cognitive decline, separate from those genes that directly influence the accumulation of AD pathology. These processes are different and complementary to those identified by GWAS-derived genes, as the effect of GWAS-derived single nucleotide polymorphisms on gene expression in this case is limited.
The central finding of this project is the existence of a robust set of coexpressed genes, supported by multiple other datasets, that is related to both β -amyloid burden and the slope of cognitive decline in older individuals. Since modeling cognitive decline in vitro is challenging, we explored the relationship of a subset of genes that were predicted to be influential genes in relation to β -amyloid biology within m109. Two of these genes, INPPL1 and PLXNB1, showed relationships to extracellular β -amyloid levels in astrocyte cultures, an intriguing preliminary result that now requires further investigation. We note that the overall conclusions of this study are strongest at the systems level and that more in vitro experiments and careful selection of additional model systems will be needed to test the regulatory structure of this system as a whole.
PLXNB1 is a member of a family of proteins that mediate semaphorin signaling, which plays a role in neuronal processes including neurite outgrowth, remodeling and synaptic plasticity 34 . However, little is known about its potential contribution to cognitive decline and AD. INPPL1, also called SHIP2, is a lipid phosphatase that regulates the levels of the important second messenger phosphatidylinositol-3,4,5-trisphosphate. Levels of this second messenger in turn regulate downstream AKT and GSK3β signaling pathways, and AKT is also a member of the m109 module. INPPL1 is important in insulin signaling, and polymorphisms in the INPPL1 gene are associated with type 2 diabetes mellitus 35 . Transgenic mice overexpressing INPPL1 show a disruption in insulin and insulin-like growth factor 1 (IGF1) signaling mediated via AKT in cultured neurons, and these mice show impaired memory 36 . Furthermore, administration of an INPPL1 inhibitor in a mouse model of diabetes was able to rescue the synaptic plasticity and memory defects observed in this model. While these published studies are centered on neurons and not the astrocytes that our shRNA study implicates, they elaborate a picture of how INPPL1 may play a multifaceted role in AD.
In previous work, we found evidence of decreased response to IGF1 in brains from persons with mild cognitive impairment and AD dementia relative to controls, regardless of diabetes status 37 . Specifically, levels of post-translationally modified forms of the IGF1 receptor were positively related to β -amyloid and negatively related to episodic and working memory, after adjusting for AD pathology. In line with these findings, we now provide evidence that the INPPL1 gene plays a role in cognitive decline and β -amyloid accumulation, and it opens new avenues for investigating the relation of phosphoinositides, insulin signaling and AD.
It is also important to note the limitations of our approach. First, assessing the false positive rate of MTN or other similar methods would require experiments on a large set of predicted null targets, which is currently cost prohibitive. Also, the MTN framework acts to increase network accuracy by modeling networks at two resolutions (a zoomed-out module-trait network and a zoomed-in gene network within selected modules), but increased accuracy comes at the price of including only a subset of modules in the inference process, resulting in potential loss of information. Additionally, an important biological limitation is that we functionally screened m109 genes for effects on in vitro β -amyloid extracellular levels when their strongest effects were on cognitive function. This study thus interrogates only part of m109's function.
In summary, we completed the initial arc of molecular network discovery and validation, and we have illustrated the use of the network in prioritizing a module, m109, and a small subset of genes within it for functional assessment. INPPL1 and PLXNB1 are intriguing candidates that we have connected to amyloid biology in vitro and now require further evaluation to assess their potential as AD therapeutic targets. This report is therefore an initial blueprint for a quantitative systems approach to investigating the pathobiology and function of the aging human brain.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41593-018-0154-9.
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was performed on the Illumina HiSeq with 101-bp paired-end reads and achieved coverage of 150 million reads of the first 12 samples. These 12 samples will serve as a deep coverage reference and included 2 males and 2 females with unimpaired, mildly cognitively impaired and AD diagnoses each. The remaining samples were sequenced with a target coverage of 50 million reads; the mean coverage for the samples passing QC is 95 million reads (median 90 million reads). The libraries were constructed and pooled according to the RIN scores such that similar RIN scores would be pooled together. Varying RIN scores results in a larger spread of insert sizes during library construction and leads to uneven coverage distribution throughout the pool. RNA-seq data were processed by our parallelized pipeline. This pipeline includes trimming the beginning and ending bases from each read, identifying and trimming adaptor sequences from reads, detecting and removing rRNA reads, and aligning reads to the reference genome. The non-gapped aligner Bowtie was used to align reads to the transcriptome reference 49 , and RSEM was used to estimate expression levels for all transcripts 50 . The FPKM values were the outcome of our data RNA-seq pipeline.
To remove outlier samples based on quantified expression profiles, following a previous approach 51 , the D-statistic was computed as the median correlation of all genes (based on expression profiles) of each sample with all other samples. An additional 13 samples with D-statistics < 0.9 were deemed outliers and excluded.
For the 2 individuals with replicate samples, we took (at random) only one of the replicates, and we excluded 19 samples without genotyping data. Thus 508 unique samples were analyzed for derivation of gene modules. For trait analysis, we further excluded 30 samples for which clinical and/or pathological assessment was not complete, resulting in 478 brain samples (unique individuals) analyzed with respect to AD traits.
RNA-seq data normalization.
We applied quantile normalization to FPKM first and then used the Combat algorithm 52 to remove potential batch effect. Expression levels were quantified for 55,889 unique genes and 190,051 transcripts. We placed a threshold for expression, keeping only genes with at least 4 reads in 100 individuals (yielding 13,484 significantly expressed genes).
After quantile normalization and batch correction, we used linear regression (on log 2 expression data) to remove the effect of major biological and technical confounding factors on a per-gene basis. Biological confounding factors include three genotyping PCs (to represent ancestry), age at death and sex. Technical confounding factors include RIN, number of ribosomal bases, number of aligned reads, study index (ROS or MAP) and postmortem interval.
In addition to known confounding factors, previous studies have shown that in some cases removal of hidden confounding factors (for example, 'surrogate variables' 53 ) can increase statistical power (for example, the consistent reported increase in statistical power for cis-eQTL studies 54 ). These hidden factors can be estimated by the top expression PCs (or factors) 53, 55, 56 . Here, for reasons described below, we did not find sufficient evidence to normalize for potential hidden confounds.
First, we hypothesized that if the removal of expression PCs does indeed improve the identification of disease-associated genes (either through reducing false positives or increasing statistical power), then as we remove expression PCs we should see an increase in the strength of the association between known AD genes and AD traits. Therefore, we assessed the differential expression of 32 known AD genes (from literature and GWAS) after removing from 1 to 10 expression PCs. Removal of PCs generally degraded the association strengths ( Supplementary Fig. 1a ). Second, we noted that the top expression PCs correlate with known cell type markers. Therefore, without explicitly adjusting for expression PCs, some of the estimated modules represent patterns that are predictive of cell type proportions (Supplementary Table 6 ). As described in the main manuscript, our approach uses these 'cell-specific' modules to correct for cell type composition changes-we reasoned that for a cell-specific module, the relative expression across individuals is indicative of proportion of the represented cell type. We think that this post hoc approach for assessing cell type proportion presents a powerful method for identifying interesting cell types and conservatively correcting for cell type proportion changes that may lead to differential expression. Third, we noted that after removing the top few PCs, clustering algorithms tended to produce many small clusters or modules (modules with few gene members). Thus, we chose to only account for known covariates and not any hidden covariates. Hidden covariates are captured by broad modules that represent cell types, and they are analyzed in a post hoc manner.
Association analysis. Randomization. There was no randomization as we are analyzing data from all available participants in a prospective, longitudinal study. No subjects had dementia at study entry.
Software. All software used in our analyses is publicly available and referenced below where it is discussed. There was no new software written for this manuscript.
Transcriptome-wide association study analysis. For continuous traits (β -amyloid, tau tangles and cognitive decline), we used Spearman rank correlation (and the associated P values) to quantify the strength of associations between each gene's Methods ROSMAP pathology and clinical traits. Amyloid and tau. To quantify an estimate of the burden of parenchymal deposition of β -amyloid and the density of abnormally phosphorylated tau-positive neurofibrillary tangles levels present in the cortex at death (which we refer to as β -amyloid and tau tangles, respectively), tissue was dissected from eight regions of the brain: the hippocampus, entorhinal cortex, anterior cingulate cortex, midfrontal cortex, superior frontal cortex, inferior temporal cortex, angular gyrus and calcarine cortex. Sections 20 µ m thick from each region were stained with antibodies to the β -amyloid protein and the tau protein, and quantified with image analysis and stereology as previously described 14, [38] [39] [40] . Briefly, β -amyloid was labeled with an N terminus-directed monoclonal antibody (10D5; Elan, Dublin, Ireland; 1:1,000). Immunohistochemistry was performed using diaminobenzidine as the reporter, with 2.5% nickel sulfate to enhance immunoreaction product contrast. Between 20 and 90 video images of stained sections were sampled and processed to determine the average percentage of the area positive for β -amyloid. PHFtau was labeled with an antibody specific for phosphorylated tau (AT8; Innogenetics, San Ramon, CA; 1:1,000). Between 120 and 700 grid interactions were sampled and processed, using the stereological mapping station, to determine the average density (per mm 2 ) of PHFtau tangles. The scores across the eight regions were averaged, for amyloid and tau separately, to create a single summary measure for each protein. To create approximately normal distributions and facilitate statistical comparisons, we analyzed the square root of these two summary measures.
Cognitive decline. The ROS and MAP methods of assessing cognition have been extensively summarized in previous publications 16, 18, 39, 41, 42 . Uniform structured clinical evaluations, including a comprehensive cognitive assessment, are administered annually to the ROS and MAP participants. Scores from 17 cognitive performance tests common to both studies were used to obtain a summary measure for global cognition, as well as measures for five cognitive domains of episodic memory, visuospatial ability, perceptual speed, semantic memory and working memory. The summary measure for global cognition is calculated by averaging the standardized scores of the 17 tests, and the summary measure for each domain is calculated similarly by averaging the standardized scores of the tests specific to that domain. To obtain a measurement of cognitive decline, the annual global cognitive scores are modeled longitudinally with a mixed effects model, adjusting for age, sex and education, providing person-specific random slopes of decline. The random slope of each subject captures the individual rate of cognitive decline after adjusting for age, sex and education. Further details of the statistical methodology have been previously described 43 .
Pathologic diagnosis of AD. A pathologic diagnosis of AD was determined by a board certified neuropathologist blinded to age and all clinical data and using modified Bielschowsky silver-stained 6-μ m sections of hippocampus, entorhinal cortex, midfrontal cortex, midtemporal cortex and inferior parietal cortex. The diagnosis follows the recommendation of the National Institute on Aging Reagan criteria 44 . Briefly, based on the scores of Braak stage for severity of neurofibrillary tangles and CERAD estimate for burden of neuritic plaques, a pathologic AD diagnosis requires an intermediate likelihood AD (i.e., at least Braak stage 3 or 4 and CERAD moderate plaques) or a high likelihood AD (i.e., at least Braak stage 5 or 6 and CERAD frequent plaques).
Clinical diagnosis of AD at the time of death. Annual clinical diagnosis of AD dementia follows the recommendation of the joint working group of the National Institute of Neurological and Communicative Disorders and Stroke and the AD and Related Disorders Association 45 . The diagnosis requires a history of cognitive decline and evidence of impairment in memory and at least one other cognitive domain. After a participant died, a neurologist specializing in dementia reviewed all available clinical information and provided a summary opinion with regards to the most likely clinical diagnosis at the time of death. The summary diagnosis was blinded to all neuropathologic data, and case conferences were held for consensus as necessary 46 . AD dementia includes persons with probable or possible AD dementia-i.e., AD dementia with or without comorbid conditions that may be affecting cognition.
ROSMAP RNA-seq data quantification and QC. We did not use a power calculation to determine the size of our study. We processed samples from each individual with an available sample of frozen dorsal lateral prefrontal cortex (DLPFC) at the time data generation occurred.
The laboratory personnel generating the RNA sequence data were blinded to the phenotypic data available for each subject.
RNA was sequenced from the gray matter of DLPFC of 542 samples, corresponding to 540 unique brains. These samples were extracted using Qiagen's miRNeasey mini kit (cat. no. 217004) and the RNase free DNase Set (cat. no. 79254). RNA was quantified using Nanodrop. Quality of RNA was evaluated by the Agilent Bioanalyzer. All samples were chosen to pass two initial quality filters: RNA integrity (RIN) score > 5 and quantity threshold of 5 μ g; samples were selected from a larger set of 724 samples. RNA-seq library preparation was performed using the strand-specific dUTP method 47 with poly(A) selection 48 . Sequencing Articles NATURe NeURoscieNce (or transcript's) expression levels and a given trait (Supplementary Table 2 ). We used a t-test to assess the association between binary traits (diagnosis status) and gene expression levels. We noted that tau pathology was associated with a much smaller set of genes than β -amyloid pathology.
Module-to-trait association analysis. Each module (see below for module derivation) is first represented by the mean expression level of all genes assigned to that module (expression data is standardized before computing module means). Then the module's mean expression vector is associated with each AD trait, using the Spearman correlation for continuous traits and Pearson correlation (whose P value is equivalent to a t-test) for binary traits.
Deriving gene modules and assessing their quality. We used the SpeakEasy (SE) consensus clustering algorithm 20 to derive gene modules from normalized gene expression data. We quantify the consensus clustering results from 100 initializations of the SE algorithm, which produced 257 modules, 47 of which contained at least 20 gene members (meaning modules with > 20 members are assigned for 98% of genes) and were examined in downstream analyses (visually summarized in Supplementary Fig. 3 ). The assignments of gene to modules are provided in Supplementary Table 3 .
We used the SE algorithm because it was recently shown to represent the state of the art in terms of identifying robust clusters in the Lancichinetti-Fortunato-Radicchi (LFR) benchmarks, as well as in a wide range of biological networks. Specifically, on these previous benchmark experiments, the SE algorithm outperformed standard hierarchical clustering algorithms and their derivatives such as WGCNA 21 . But on the ROSMAP RNA-seq data, we also investigated the degree to which the clustering solutions of SE overlap with those produced by the WGCNA 21 algorithm. Because individual cluster-to-cluster comparison metrics can be highly unstable, we compare the overall similarity across all clusters identified by SE and WGCNA collectively ( Supplementary Table 4 ). To make the comparison even more robust, we used multiple proposed measures of partition similarity 57 .
These results indicate a significant similarity between SE and WGCNA, but to a lesser extent than variation between WGCNA runs under slightly different parameter setting. Thus, our clustering results carry a similarity to those of the previous WGCNA method but, based on performance benchmark comparisons and a wide range of real-world networks, are likely to be more accurate.
Module functional enrichment analysis. For each module and gene set, we computed a hypergeometric enrichment P value for enrichment in any gene ontology category, and we used a Bonferroni-adjusted P < 0.01 to identify significantly enriched functions for each module. We used all DLPFC expressed genes (identified in this study) for a 'background' set. According to this analysis, 29 of the 47 modules (or 62% of the modules) were significantly enriched for at least one Gene Ontology category, which covers 8,368 genes (also 62% of expressed genes) (see Supplementary Table 5 ).
Cell type composition and relationship with gene modules. Random variation in the proportion of cell types across samples (individuals) can lead to identification of modules that are enriched in genes that are highly expressed in particular cell types. To assess which of the modules have some relationship to cell types, we calculate the median rank of all genes in a module in the rank-ordered expression of genes in a given cell type (see below for sources of cell-type-specific gene expression). We repeat this calculation for all combinations of modules and cell types. This provides an indicator of when modules contain genes that are highly expressed in a canonical cell type. Because modules generally consist of hundreds of genes, this test is well powered to detect even minor enrichment, with nearly every module showing significant enrichment for some cell type, down to the minimum P value (based on 10,000 permutations). Therefore, we also provide a practical measure of enrichment effect size, which is the increase in the median rank of genes in a module in the sorted expression of genes from a given cell type compared to the median rank from permuted gene sets. In our analysis, we use an effect size of 1.4 to identify cell-type-associated modules. We chose the 1.4 threshold because we found that at this threshold, each of the main brain cell types (astrocyte, microglia, oligodendrocytes and neurons) will be represented by at least one module. Supplementary Table 6 provides the results of this analysis.
The origin of the cell type signatures is gene expression from mouse brain, wherein cell types are better annotated with marker genes than in humans and where a larger amount of transcriptome cell type profiles are available. We downloaded 18 large appropriate datasets from GEO on the Affymetrix 430 GeneChip (microarray) platform, which were applied to measure gene expression in a range of common cell types in the mouse brain [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] . These cell types were captured by a range of methods, including fluorescence-assisted cell sorting and laser capture microdissection. These data were often generated from disease models or mice exposed to various perturbations. Single-cell RNA-seq is an excellent mechanism to identify cell types in an unbiased manner, but for our purpose the largest brain cell type studies in GEO do not sequence deeply enough to be useful: they show distinct expression for a few thousand genes, compared to the twenty thousand surveyed on the microarrays. To generate a genomic signature for each cell type, we simply take the median value across all replicates of a gene cell type.
For our intended use of validating the coherence of expression among our inferred modules, cell type enrichment is a useful tool that shows substantial coherence of cell-type-specific expression and module membership. For purposes beyond validating the plausibility of clustering results, additional caution is needed for interpreting these results. Negative findings for a module with regard to cell type should not be seen as conclusive, due to the cross-species nature of the comparison, but positive findings with large effect sizes are likely to be meaningful. Conversely, positive findings do not necessarily indicate the literal presence of a given cell type. Indeed some cell types, such as Bergmann cells, would not be expected to be found in the frontal cortex; however, they may utilize some subcellular system that is represented by a coexpression module derived from cortex. For instance, due to the high metabolic demands of fast spiking, PV + (parvalbumin-positive) cells have an abundance of mitochondria. Thus a module related to mitochondria may show up as enriched in genes highly expressed in PV + cells, although that module may well be driven by mitochondrial levels in a different cell type, or by mitochondrial function across cell types. In other cases, module enrichment in cell-type-specific genes may literally indicate the large presence of that cell type in the frontal cortex, such as in the case of module 116, which contains many genes that when perturbed indeed result in effects in microglia 12 .
Replication of gene modules. We used the module preservation statistic 22 to assess whether a given module is preserved in a second (validation) dataset ( Supplementary Fig. 4a ). The module preservation statistic (called 'z-summary') combines multiple metrics that assess the conservation of coexpression patterns within a given module in a second (validation) dataset. As validation data, we employed four datasets: (i) microarray gene expression data from cortex (DLPFC) from a previous study by Zhang and colleagues 12 , (ii) microarray gene expression data from mouse brain from a previous study by Matarin and colleagues 24 , (iii) an independent test dataset from the ROSMAP study (unpublished, data available from Synapse https://doi.org/10.7303/syn3388564) and (iv) histone modification data (H3K9ac chromatin immunoprecipitation followed by sequencing, unpublished, available at https://doi.org/10.7303/syn4896408). We summarize the analyses of these data below.
Microarray DLPFC dataset. Processed microarray gene expression data and metadata were downloaded from GEO (accession GSE44772) 12 . Metadata included a pathology variable (binary), age, gender and brain region. Using linear regression (on log 2 expression data), we removed the effect of age and gender, and analyzed 229 samples from the DLPFC region. 10,330 measured genes overlapped with genes defined as expressed in the ROSMAP dataset (this study).
Mouse brain gene expression dataset.
We used the mouse gene expression datasets generated by Matarin and colleagues 24 . We only used gene expression data generated from cortex, which resulted in 112 samples and included 38 control mice and 74 transgenic mice (mutant human APP, PSEN1, APP PSEN1 double transgenic, and mutant human MAPT gene). For the purpose of module preservation statistic, all 112 samples were used to compute module preservations.
Module coherence in ROSMAP test samples. We used 82 samples from the ROSMAP project that were not included in the primary analysis. These samples were extracted and quantified after the initial data freeze for the primary analysis. These 82 samples were processed the same way as the samples used in the primary analysis: we accounted for the same set of technical and biological confounds in these samples using linear regression. The RNA-seq data from these 82 samples are available from the Synapse database (reference number syn3505724).
Histone modification (acetylation) data. Histone acetylation data using ChIP-seq (H3K9ac chromatin immunoprecipitation followed by sequencing) were available for 712 samples. To quantify histone acetylation, after sequencing, single-end reads were aligned by the BWA algorithm 76 against the human reference genome GRCh37. Peaks were detected in each sample separately by MACS2 77 using the broad peak option and a q-value cutoff of 0.001. Pooled genomic DNA of seven samples was used as negative control. A combination of five ChIP-seq quality measures were employed to detect low quality samples: we removed samples that did not reach (i) ≥ 15 × 10 6 unique reads, (ii) nonredundant fraction ≥ 0.3, (iii) cross-correlation ≥ 0.03, (iv) fraction of reads in peaks ≥ 0.05 and (v) ≥ 6,000 peaks. In total, 669 out of 712 samples passed quality control. 441 of the 669 samples overlap with RNA-seq samples. H3K9ac domains were defined by calculating all genomic regions that were detected as a peak in at least 100 (15%) of the 669 samples. Regions neighboring within 100 bp were merged and very small regions of less than 100 bp were removed. To map peaks to genes, we identified the closest peak to the TSS of each gene. Finally, quantified histone acetylation data was quantile normalized to account for variability in sequencing depth across individuals. To quantify the preservation of each module, we considered the 'coacetylation' signal at the closest peak to each gene. These histone modification data are publicly available from the Synapse database (reference number syn4896408).
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Replication of module-to-trait relationships. We used a previous microarray data by Zhang et al. 12 (consisting of 229 samples-see above) to replicate the associations between modules and AD traits. In particular, we used the module memberships for the 47 modules identified in the ROSMAP samples to compute the mean of each module in the Zhang et al. dataset (as above, module means are computed after standardization of gene expression data). Then the mean expression vector for each module was associated with relevant AD traits. Moduleto-trait relationships were highly reproducible (Fig. 2d ).
Using the Zhang et al. 12 study, we also compared the replication modulelevel trait associations with gene-level trait associations. In particular, as a test statistic for module-level replication, we computed the correlation between two vectors: a vector of length 47 (number of modules) representing the association between each module and the binary pathology variable in this study, and a vector of length 47 representing the association between each module and the binary pathology variable using data from the Zhang et al. study. The Spearman correlation between these two vectors is 0.9. To compare this to gene-level analysis, we performed a resampling-based analysis: we randomly sampled 47 genes (among the 10,330 genes that overlap between this study and the Zhang study) 10,000 times and computed the correlation between gene-totrait vectors in this study and Zhang et al. study. Module-level analysis was significantly more concordant between the two studies, as compared to the gene-level analysis ( Supplementary Fig. 4b) .
Conditional association analysis. To assess the correlation between the expression level of m109 module and pathology/AD while conditioning on the APOE haplotype, we used multiple regressions in sequence, with the first being unadjusted for APOE haplotype and the second being adjusted for APOE haplotype. We then compared the effect size and P value in the adjusted regression versus that of the unadjusted regression. For each regression, we modeled m109 as the independent variable and pathological AD or cognitive decline as the outcome variable. In adjusted analyses, we added APOE haplotype as a covariate. We used logistic regression to analyze pathological AD and linear regression for cognitive decline.
To assess the correlation between the expression level of the m109 module and cognitive decline when accounting for neuropathology (β -amyloid levels), we also performed multiple regressions in sequence. In the first regression we modeled cognitive decline as the dependent variable and m109 as the independent variables, and in the second we added amyloid burden as a covariate in the model. We then compared the effect size and P value of m109 on cognitive decline in the unadjusted model versus that of the adjusted model.
Bayesian network structure learning to compute the module-trait network.
A Bayesian network is a probabilistic graphical model that represents a set of random variables and their conditional dependencies using a directed acyclic graph (DAG). Bayesian structure learning algorithms (such as the MCMC algorithm used here 78 ) enable the estimation of the DAG that describes the conditional dependencies between a set of random variables in a data-driven manner. Here we used Bayesian network structure learning to estimate the DAG that describes the relationship between three types of variables: modules, cell type proportions and AD traits. In particular, we included 11 modules in the DAG that were significantly associated with at least one of the three main ADrelated traits (β -amyloid, tau tangles and cognitive decline), after accounting for multiple testing with the Bonferroni procedure. As described above, some of the modules are enriched for known cell-type-specific genes and thus their expression levels may present a proxy for cell type proportions (and their variability across individuals in this study). Therefore, we included four cell-specific modules that enable us to model cell-type-specific changes. We chose these modules as the ones with the most 'fold enrichment' for the four main brain cell types: neurons (m187), astrocytes (m107), microglia (m116) and oligodendrocytes (m123). There were several modules associated with one of the neuronal subtypes (Fig. 2b) ; however, many of these modules had correlated expression profiles. We reasoned that in the absence of experimental data measuring the proportion of each of the neuronal subtypes in our samples for validation, we do not have the resolution to accurately model each of the neuronal subtypes in the Bayesian network analysis. Therefore, we chose to select the most enriched module for any of the neuronal cell types (m187) to broadly represent 'proportion of neuronal cells' in the Bayesian network analysis.
The ensemble MCMC approach used here was recently shown to be among the state-of-the-art algorithms for Bayesian network structure learning when applied to gene expression data 78 . The essential difference between the REV move method we employ 79 and classic structure learning is that, for each revision of the proposed gene-gene network, the REV algorithm proposes larger changes to the evolving network structure. The benefits of these extensive updates and the specific type of network alterations is to avoid becoming trapped in a locally optimum solutionwhich has been demonstrated using simulated gene expression data analogous to ROSMAP 78 . Using this approach, we ran structure learning 100 times with stochastic initialization. The final Bayesian network was selected using Bayesian model averaging 80 , and we also visualize the raw edge count among the 100 models as edge width (Fig. 3a) .
Identifying target genes in module 109. The Bayesian network structure learning framework described above identified module 109 (m109) as the module that is most strongly associated with cognitive decline and amyloid. Additionally, we confirmed that the association between m109 and amyloid is not simply explained away by variability in cell type proportions as captured by expression levels of standard cell type markers. Thus, we reasoned that m109 is the module most directly associated with cognitive decline and amyloid load in this sample. Therefore, we devised an approach to prioritize genes in m109 (which contains 390 genes) for experimental validation as described below.
First, we reduce the number of plausible genes by taking the top 112 genes (among the 390 genes assigned to m109) that (i) are most strongly associated with cognitive decline and amyloid load and (ii) are connected to other genes in an initial Bayesian network of 390 genes. Next, we construct a Bayesian network for representing conditional dependencies between these 112 genes in a DAG (Fig. 4a) . The DAG enables us to rank genes according to their number of conditional dependent connections to other genes in the module. As rationalized in previous studies 12 , we selected genes with the highest number of connections ( Supplementary Table 8 ) as nodes likely to influence the expression of many other genes and consequently the biological function of the module. We then further filtered these to 21 tested genes based on sufficient expression (FPKM > 1) in the astrocyte or induced neuron in vitro model as well as the availability of efficient shRNAi constructs for knockdown experiments ( Supplementary Tables 9 and 10 ).
Experimental validation of target genes. Cell culture. Induced pluripotent stem cells (iPSCs) were maintained in iPSC medium consisting of 400 mL DMEM/F12, 100 mL Knockout Serum Replacement, 5 mL penicillin/streptomycin/glutamine, 5 mL MEM-NEAA and 500 μ L 2-mercaptoethanol (all from Invitrogen) with fresh addition of bFGF (Millipore) at 10 μ g/mL. Differentiation was carried out as previously reported by Zhang et al. 12 with minor modifications. iPSC-derived neurons were plated at DIV4 on Matrigel-coated 96-well plates (25,000 cells/well) and maintained in medium consisting of 485 mL Neurobasal medium (Gibco), 5 mL Glutamax, 7.5 mL 20% dextrose, 2.5 mL MEM NEAA with 1:50 B27, BDNF, CNTF, GDNF and doxycycline added just before use.
Human cortical astrocytes were obtained from Sciencell and cultured in basal medium containing 2% FBS, 1% penicillin/streptomycin and 1% astrocyte growth supplement (Sciencell). Astrocytes were trypsinized and plated at a density of 40,000 cells/well of a 96-well plate and maintained for no more than 7 d. Viral transduction. To perturb gene targets, astrocytes were plated 1 d before transduction by 10 μ L of lentivirus (shRNA titer range 1.4 × 10 7 -3.43 × 10 8 virus particles/mL; ORF titer range 6.82 × 10 6 -4.3 × 10 7 virus particles/mL) in 40 μ L of growth medium. iPSC-derived neurons were transduced on DIV17 with 25 μ L virus in 25 μ L growth medium. After ~18 h, virus-containing medium was removed and replaced with fresh medium and cells incubated for an additional ~96 h. Conditioned medium was collected and stored at -20 °C, while cells were lysed for either RNA or protein purification.
qPCR. Samples were prepared for qPCR using the Power SYBR Green Cellsto-Ct kit (Ambion) according to the manufacturer's instructions. qPCR was performed using Fast SYBR Green Master Mix (Applied Biosystems) and three technical repeats assessed with a ViiA 7 System (Applied Biosystems). Relative expression was calculated using the Δ Δ Ct method as described in ref. 81 and GAPDH normalization.
Immunocytochemistry and microscopy. Cells were fixed in 4% paraformaldehyde (Sigma) and permeabilized in 0.1% Triton X-100 in donkey serum (Jackson ImmunoResearch) before overnight incubation with primary antibodies. Following secondary antibody incubation for 1 h, cells were treated with DAPI. Images of immunocytochemically stained and fluorescent-protein-expressing cells were collected using a Zeiss LSM710 confocal microscope and ZEN black software. We used, for ALDH1L1, an eBioscience antibody, catalog number 14-9595-82, lot E17095-102; for PLXNB1, a Sigma antibody, catalog number HPA040586, lot R36823, and for INPPL1, a Novus Biological antibody, catalog number NBP1-87046, lot R36379. These antibodies have been validated for use in human samples in immunohistochemistry, and the specificity of antibodies was tested using negative control.
Aβ ELISA. To determine the secreted Aβ peptide concentrations, conditioned medium generated from cells having undergone viral transduction was subjected to 6E10 Aβ peptide panel multiplex ELISA following manufacturer's instructions (Meso Scale Discovery). Wells were blocked before 2-h incubation of detection antibody solution with sample conditioned medium or standard. Plates were read using an MSD SECTOR Imager 2400 and resulting peptide concentrations were normalized to total protein for each sample.
Statistical analysis. Aβ 42 secretion levels were measured in 6 batches for the discovery dataset, with each batch containing up to 11 control samples ( Supplementary Table 11 ). These control samples consist of three different types 1 nature research | reporting summary 
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Sample size
n=508. We used all samples for which RNA-seq, genotype, and phenotype data are available. These samples represent all subjects with available frozen brain samples at the time of data generation.
Data exclusions All data meeting pre-determined quality control criteria were included for analysis.
Replication
As described in the paper, several independent datasets were used to replicate the module assignment and the associations between module expression and measurable phenotypes.
Randomization There is no randomization. The analyses are based on participants who are participants in one of two prospective cohort studies. All participants with an available sample were used in the analyses.
Blinding
The team members generating the data from the biological samples were blinded to the phenotypic data of each participant. Only the analyst had access to the molecular and phenotypic data to perform the planned analyses.
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Validation
Antibodies have been validated for use in human samples in immunohistochemistry and the specificity of antibodies were tested using negative controls.
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Cell line source(s)
The YZ1 iPSC line was acquired from the UCONN stem cell core. This line had a small percentage of cells with a karyotype abnormality. Therefore, the lines was then monoclonally subcloned to generate cells with a normal karyotype prior to beginning these studies (and subsequently deposited into WiCell. Human primary astrocytes were obtained from ScienCell.
Authentication PSC lines were karyotyped, and authentification was performed using STR analysis through Genetica Cell Line Testing.
